Google's earnings miss weighed the markets down to a lower close with the Dow slipping 8 points to 13,548. Nasdaq tumbled 31 points to 3072. On the upside
A Food and Drug Administration advisory panel recommended approval of Aegerion's (Nasdaq: AEGR) cholesterol treatment lomitapide. USG (NYSE: USG) narrowed third quarter losses as revenue rose. Rumors circulated that Juniper Networks (NYSE: JNPR) may be acquired by EMC (NYSE: EMC). On the downside Lexicon Pharmaceuticals (Nasdaq: LXRX) priced its public offering of 17.5 million common shares at the discounted price of $2.25 per share. Third quarter earnings rose for BB&T (NYSE: BBT) but the results fell short of analyst expectations. CytRx (Nasdaq: CYTR) priced its offering of 8 million common shares at the discounted price of $2.50 per share. In the broad market, declining issues outpaced advancers by a margin of nearly 10 to 9 on the NYSE and by more than 2 to 1 on Nasdaq. The Russell 2000 which tracks small cap stocks fell 5 points to 837.